title: Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment.
abstract: We report here a rare case of a young male patient presenting with a Multiple Endocrine Neoplasia Type 1 - prolactin-secreting pituitary carcinoma, controlled long-term after temozolomide withdrawal. Initial presentation was pituitary apoplexy leading to surgery. Dopamine agonists and radiotherapy allowed control of prolactin secretion and pituitary remnant. Metastasis appeared 10 years after initial presentation, leading to the diagnosis of pituitary carcinoma. At that time, dopamine agonists were no more effective; temozolomide, an oral alkylating agent, was administered for 24 cycles, and allowed decrease of the volume of the pituitary lesion and metastases. The patient is still currently followed in our department, 3 years after temozolomide withdrawal: prolactin level and pituitary tumor volume remain controlled without any chemotherapy. To our knowledge, this is the first case of MEN1 prolactin secreting pituitary carcinoma controlled long-term after temozolomide discontinuation.
authors.affiliation: Department of endocrinology and reference center for rare pituitary diseases, hôpital Timone, assistance publique hôpitaux de Marseille, Aix-Marseille université, 13284 Marseille, France.
authors.forename: Melanie
authors.initials: M
authors.lastname: Philippon
authors.forename: Isabelle
authors.initials: I
authors.lastname: Morange
authors.forename: Marilyne
authors.initials: M
authors.lastname: Barrie
authors.forename: Anne
authors.initials: A
authors.lastname: Barlier
authors.forename: David
authors.initials: D
authors.lastname: Taieb
authors.forename: Henry
authors.initials: H
authors.lastname: Dufour
authors.forename: Bernard
authors.initials: B
authors.lastname: Conte-Devolx
authors.forename: Thierry
authors.initials: T
authors.lastname: Brue
authors.forename: Frédéric
authors.initials: F
authors.lastname: Castinetti
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000150:complications / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000532:radiotherapy / Q000601:surgery; D003131:Combined Modality Therapy; D016371:Cranial Irradiation; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000627:therapeutic use; D020249:Hormone Replacement Therapy; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy / Q000209:etiology; D007016:Hypophysectomy / Q000009:adverse effects; D007018:Hypopituitarism / Q000188:drug therapy / Q000209:etiology; D008297:Male; D018761:Multiple Endocrine Neoplasia Type 1 / Q000188:drug therapy*; D020125:Mutation, Missense; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009886:Ophthalmoplegia / Q000209:etiology; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D010282:Parathyroid Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D010899:Pituitary Apoplexy / Q000209:etiology; D010911:Pituitary Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000532:radiotherapy / Q000601:surgery; D011388:Prolactin / Q000378:metabolism; D011518:Proto-Oncogene Proteins / Q000235:genetics; D018714:Radiotherapy, Adjuvant; D012074:Remission Induction; D013125:Spinal Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D000077204:Temozolomide
chemical_list: D000970:Antineoplastic Agents; D018491:Dopamine Agonists; C105373:MEN1 protein, human; D011518:Proto-Oncogene Proteins; D003606:Dacarbazine; D011388:Prolactin; D000077204:Temozolomide